Phase 3 Trial Reduces Risk of Progression in Metastatic Prostate Cancer

16 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
Advances in Care host Erin Welsh is joined by Dr. Scott Tagawa, medical oncologist at NewYork-Presbyterian and director of the Genitourinary Oncology Program at Weill Cornell Medicine, to talk about the latest developments in prostate cancer care. Dr. Tagawa recently led a Phase III randomized trial– called PSMAddition–to assess targeted radioligand therapy in men with hormone-sensitive metastatic prostate cancer, which yielded notable declines in PSA levels and slowed cancer progression by 28%. The use of this therapeutic earlier in treatment as opposed to a last-line defense has the potential to redefine the standard of care and improve outcomes for patients with metastatic prostate cancer.

#prostatecancer #radioligandtherapy #clinicaltrials #psma #newyorkpresbyterian
Categoria
Oncology
Commenta per primo questo video.

Prossimo